Skip Navigation


European Heart Journal Advance Access originally published online on February 20, 2006
European Heart Journal 2006 27(6):641-643; doi:10.1093/eurheartj/ehi812
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/6/641    most recent
ehi812v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Clark, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Right arrow Articles by Clark, A. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Threats, opportunities, and statins in the modern management of heart failure

John G.F. Cleland*, Huan Loh, Jonathan Windram, Kevin Goode and Andrew L. Clark

Department of Cardiology, Castle Hill Hospital, University of Hull, Kingston-upon-Hull, UK

* Corresponding author. Tel: +44 1482 624 084; fax: +44 1482 624 085. E-mail address: j.g.cleland@hull.ac.uk

This editorial refers to ‘Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy’{dagger} by M. Christ et al., on page 691

The first 10% of the full text of this article appears below.

Effective management of heart failure is becoming increasingly complex. Polytherapy, both pharmacological and device-based, should now be the standard practice for the management of most patients with heart failure.1 This requires considerable medical expertise, training, and organization of care. Unfortunately, although heart failure is a highly malignant and treatable condition, its management is poorly resourced and organized compared with cancer.2,3

Further developments in the provision of care for patients with heart failure carry threats and opportunities. One important threat is that the complex polypharmacy could lead to more confusion, more adverse drug effects, and more drug interactions. For instance, even though spironolactone has been shown to be effective in clinical trials, and to save lives, its use without proper monitoring may increase . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy
Michael Christ, Theresia Klima, Wolfram Grimm, Hans-Helge Mueller, and Bernhard Maisch
EHJ 2006 27: 691-699. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 NEJMHome page
J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J. G.F. Cleland, J. H. Cornel, P. Dunselman, C. Fonseca, A. Goudev, P. Grande, et al.
Rosuvastatin in Older Patients with Systolic Heart Failure
N. Engl. J. Med., November 29, 2007; 357(22): 2248 - 2261.
[Abstract] [Full Text] [PDF]